Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 746 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glycemic Control Clear all
Not yet recruiting Not applicable Interventional

Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D.

NCT06912737
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
56
States / cities
Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

NCT01809327
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Progressive Intensity Exercise Training on Glycemic Control in Older Adults

NCT03154073
View directory record Official record
Conditions
PreDiabetes, Aging
Interventions
Moderate Intensity Exercise Training (MOD), Vigorous Intensity Exercise Training (VIG)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability

NCT05493553
View directory record Official record
Conditions
Healthy, Impaired Glucose Tolerance
Interventions
Dietary supplement regimen, Dietary supplement and intermittent fasting regimen
Dietary Supplement · Other
Lead sponsor
Unicity International, Inc.
Industry
Eligibility
30 Years to 69 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exercise and Energy Balance on 24-hour Blood Glucose Control

NCT03350997
View directory record Official record
Conditions
Metabolic Disease, Adipose Tissue
Interventions
Trial 2 Exercise, Trial 1 Exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 19, 2026, 1:03 PM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 19, 2026, 1:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Medtronic 670G Insulin Pump and the Impact on Glycemic Control, Quality of Life, and Compliance

NCT04329871
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Metabolic Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

NCT00468039
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin + metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 78 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peanuts and Glycemic Control

NCT03654651
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Peanut, High carbohydrate snack
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 19, 2026, 1:03 PM EDT
Terminated Not applicable Interventional

Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

NCT03939065
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
Interventions
Sensor Augmented Pump Therapy, Standard of Care with CGM
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

NCT00313001
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional

Heat and Exercise in Aging as Therapy (HEAT)

NCT06580964
View directory record Official record
Conditions
Prediabetic State
Interventions
Heat therapy, High-intensity interval training
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes

NCT03379792
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
19 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Orange Pomace Fiber on Glycemic Response

NCT02962375
View directory record Official record
Conditions
Healthy
Interventions
Active, Control
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 19, 2026, 1:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

NCT05776563
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Nutrition visits, Intensification of diabetes regimen, Continuous glucose monitor (CGM)
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Enrolling by invitation No phase listed Observational

Glycated Albumin Monitoring

NCT07777900
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Effectiveness of CGMS Vs. Self-monitoring Blood Glucose (SMBG) in Woman with Gestational Diabetes

NCT04948112
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy
Interventions
real time continuous glucose monitor, blinded continuous glucose monitor
Device
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence in Diabetes

NCT03983499
View directory record Official record
Conditions
Type 2 Diabetes, Glycemic Control, Cardiovascular Risk Factors, Psychological Distress
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 19, 2026, 1:03 PM EDT
Completed No phase listed Observational

Sleep Disordered Breathing and Diabetes

NCT00901472
View directory record Official record
Conditions
Type 2 Diabetes, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Not applicable Interventional

A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

NCT00308451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
Drug
Lead sponsor
Nutrition 21, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2006 · Synced Oct 19, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

NCT02926937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
56
States / cities
Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 19, 2026, 1:03 PM EDT